Giredestrant — Drug Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

3 Recruiting

8 Completed trials

5 Sponsors

17 Countries

Phase III

Phase II

Phase III: 4 Phase II: 6 Phase I/II: 1

Oversight events:

1 temporary halt 1 urgent safety measure across 2 trials

View oversight register →

Indications tested

Breast cancer 2 HER2 positive breast cancer 1 Endometrial cancer stage I 1 Endometrial cancer 1 Ovarian epithelial cancer 1 Breast cancer metastatic 1 Hormone receptor positive HER2 negative breast cancer 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 5 Genentech Inc. 2 Medica Scientia Innovation Research S.L. 2 ETOP IBCSG Partners Foundation 1 Fondazione Oncotech Impresa Sociale 1

All trials

11 total

A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting

2023-505661-89-00 Phase II 4 countries Medica Scientia Innovation Research S.L.
To compare the Safety and activity of GDC-4198 Alone and in Combination with Giredestrant against Abemaciclib and Giredestrant in Participan… Recruiting

2025-521128-31-00 Phase I/II 4 countries Genentech Inc.
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Phase III 13 countries F. Hoffmann-La Roche AG
NEOadjuvant Abemaciclib and GIredestrant triaL in patients with ER-positive, HER2-negative Early breast cancer Ended

2023-510153-42-00 Phase II 1 country Fondazione Oncotech Impresa Sociale
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended

2023-506821-12-00 Phase III 4 countries Genentech Inc.
A Study of Giredestrant in Patients with Grade 1 Endometrial Cancer Ended

2023-504091-23-00 Phase II 2 countries F. Hoffmann-La Roche AG
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Phase III 8 countries F. Hoffmann-La Roche AG
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu… Ended

2023-508194-89-00 Phase II 5 countries F. Hoffmann-La Roche AG
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Pa… Ended

2023-506911-16-00 Phase III 11 countries F. Hoffmann-La Roche AG
A Window-of-Opportunity study of hormone therapy in premenopausal women with ER-positive/HER2-negative early breast cancer. Ended

2022-503013-32-00 Phase II 7 countries ETOP IBCSG Partners Foundation
PREOPERATIVE WINDOW OF OPPORTUNITY STUDY WITH GIREDESTRANT (GDC-9545) OR TAMOXIFEN IN PREMENOPAUSAL WOMEN WITH ER[+]/HER2[-] & KI67≥10% EARL… Ended

2023-503565-36-00 Phase II 2 countries Medica Scientia Innovation Research S.L.

Showing 1–11 of 11 trials

← All drugs A–Z